As a result, our studies argue that CD151 is a suppressor of ER+ breast cancer and prostate cancer, as they frequently arise from oncogenic targeting of luminal or well-differentiated epithelial cells, rather than basal epithelial or progenitor cells. This evidence concerns the gene CD151 and prostate carcinoma.